GHK-Cu: the copper peptide, from 1973 to the research bench

GHK-Cu is the odd one out in the research-peptide catalogue: it is tiny, it contains a metal, it's older than most of the people buying it, and it is sitting in the ingredient list of thousands of cosmetics. This is what it is, what has been studied, and what to check when it's supplied for research.

What it is

GHK is a tripeptide — three amino acids, glycine, histidine and lysine, in that order. Its molecular mass is about 340 Da, which makes it roughly a fourteenth the size of an incretin peptide.

GHK-Cu is GHK with a copper(II) ion bound to it. The histidine's imidazole ring and the peptide's amino and amide groups coordinate the copper, forming a stable complex with a distinctive blue-violet colour in solution. The copper is not incidental: the complex behaves differently from the free peptide in almost every assay that has been run, and much of the research interest is in what the peptide does as a copper carrier.

It was first isolated from human plasma in 1973 by Loren Pickart, then a graduate student, who noticed that plasma from young donors did something to cultured liver cells that plasma from older donors did not, and tracked the difference to this small peptide. Its plasma concentration has since been reported to decline substantially between the ages of twenty and sixty.

What has been studied

The literature falls into three groups.

Cell culture. The best-known early work is Maquart and colleagues (1988), who reported that GHK-Cu stimulated collagen synthesis in cultured human skin fibroblasts. Subsequent cell-based studies have looked at other extracellular-matrix components, at metalloproteinases and their inhibitors, and at the behaviour of various cell types in the presence of the complex.

Gene expression. In the 2010s Pickart and co-authors used the Broad Institute's Connectivity Map — a large database of gene-expression responses to compounds — to profile GHK's effect on human gene expression. The papers report changes across a large number of genes; what those changes mean is the subject of ongoing interpretation and we don't summarise it.

Skin and wound models. Animal and ex-vivo skin studies, mostly older, examined the complex in models of wound repair. Some of this work sits behind the peptide's long-standing use in dermatological formulations.

The honest reading of the evidence is that GHK-Cu is a well-characterised molecule with a large and mostly in-vitro literature, a plausible biochemical rationale centred on copper delivery and matrix biology, and no licensed medicinal use.

The studies, broken down

"GHK-Cu is backed by decades of research" is true, and it hides the shape of that research. Sort it by the first question in how to read a peptide study, cells, animals or people, and it looks like this:

That's the pattern. Lots of cells, a handful of small animal wound models, and very little in people. What human work exists is small and topical, in cosmetic and skin-procedure settings.

Three systematic reviews published in 2026 say the same thing in their own words. One counted 20 studies: 18 preclinical and 2 randomised controlled trials. Another describes the clinical evidence as "sparse" and notes that "historical cosmetic reports are small or incompletely characterized". A third calls the human literature "thin and fragmented".

None of that means the research is wrong. It means it's early, and it's mostly about skin. So when a post talks about GHK-Cu "in studies", the useful follow-up question is always the same one: cells, animals or people?

The cosmetic context

GHK-Cu is a permitted cosmetic ingredient with the INCI name Copper Tripeptide-1, and it appears in a great many serums and creams. That is a topical cosmetic use, regulated as a cosmetic and making cosmetic claims. It has no bearing on the status of the compound when supplied as a research chemical, and a research-grade product is not a cosmetic. We mention it because buyers often encounter the name in both contexts and assume they are the same thing.

Regulatory status

GHK-Cu has no marketing authorisation as a medicine anywhere. As a cosmetic ingredient it is regulated under the UK and EU cosmetics regulations. As a research compound in the UK it may be bought, sold and held for laboratory research; it may not be sold or advertised for human or veterinary use. It is not currently on the WADA Prohibited List.

What matters for research supply

GHK-Cu adds one item to the usual list:

1. Copper content. The certificate should state the copper content or the peptide-to-copper ratio. GHK without the copper is a different material; a certificate that reports peptide purity alone is describing only half the molecule.
2. Identity. The observed mass on an HPLC-MS certificate — around 340 Da for GHK, higher for the complex — should match what's claimed. How to read the certificate.
3. Purity, with the method stated. What the number means.
4. Batch traceability — certificate, carton and the batch lookup.
5. Storage — 2–8°C, dark, do not freeze.

How Biovanta supplies it

GHK-Cu is the largest component of Glow, 70 mg — 50 mg GHK-Cu alongside 10 mg TB-500 and 10 mg BPC-157 across two pre-filled pens, with sterile needles and prep swabs. It's grouped with those two because researchers studying skin and matrix biology tend to run them together; we've described the other two compounds separately, along with what separates BPC-157 from TB-500. Manufactured in Switzerland, held refrigerated in the UK, dispatched next working day. An independent Janoshik report per batch as each completes — the testing page shows which batches have one and lets you verify it by key. Supplied strictly for in-vitro laboratory research.

Its long association with topical formulation raises a question that applies across this field: why most peptides do not survive the gut, and why a route is a chemistry decision rather than a preference.